Best of ASCO - 2014 Annual Meeting

 

Welcome

Cervical Cancer

Gynecologic Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A single-center retrospective analysis to evaluate the prognostic role of lymph node density in patients with lymph node-positive cervical cancer.

Arkadius A. Polasik

e17013

Association of detection of aflatoxin in plasma of Kenyan women with increased detection of oncogenic HPV.

Jianjun Zhiang

5530

BEATcc (ENGOT-Cx10/GEICO 68-C/GOG3030/JGOG1084): A randomized, open label, phase III study of cisplatin and paclitaxel chemotherapy with bevacizumab (CTx plus B) with or without atezolizumab (Atz) as first-line treatment for metastatic, persistent, or recurrent (m/r) carcinoma of the cervix (CCx).

Ana Oaknin

TPS5594

CALLA: Efficacy and safety of durvalumab with and following concurrent chemoradiotherapy (CCRT) versus CCRT alone in women with locally advanced cervical cancer: A phase III, randomized, double-blind, multicenter study.

Bradley J. Monk

TPS5597

Cervical cancer harboring a Rb1 mutation may sensitize to cisplatin via PI3K/AKT pathway by regulating apoptosis.

Peng Luo

5531

Cervical cancer outcomes after chemoradiation and brachytherapy in New York City comparing public versus private hospitals.

Amnon Asher Berger

e17018

Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan.

Burak Zeybek

e17028

Clinically significant discrepancy between clinical and pathologic stage of early-operable cervical cancer.

Jennifer Gibbs

5526

Comparative benefit of interstitial needles in addition to intracavitary applicators in the treatment of locally advanced cervical cancer.

Dorothy Chilambe Lombe

5528

Comparison of definitive cervical cancer management with concurrent chemotherapy and radiation between two centers with variable resources and opportunities for improved treatment delivery.

Francis Adumata Asamoah

5534

Comparison of HPV detection in HIV-infected and HIV-uninfected Kenyan women with or without cervical dysplasia.

Elkanah Omenge

e17015

Determination of eligibility criteria for salvage hysterectomy after definitive radiotherapy/concurrent chemoradiotherapy for residual cervical disease.

Munetaka Takekuma

5524

Dynamics of the immune status in patients with cervical cancer receiving complex treatment with dendritic cell vaccine.

Anna P. Menshenina

e17005

Economic burden associated with cervical cancer: An analysis of patient-reported outcomes in the United States.

Chizoba Nwankwo

e17021

Feasibility of visual inspection with acetic acid (VIA) screening for cervical cancer in Tanzania with emphasis on special populations.

Justine Chinn

5527

Human papillomavirus genotype and prognosis of invasive cervical cancer: A nationwide cohort study.

Jiayao Lei

5525

Influence of the new FIGO classification for cervical cancer on patients’ survival: Retrospective analysis of 265 histologically confirmed cases with FIGO stages Ia to IIb.

Nikolaus de Gregorio

e17006

Inpatient burden of cervical and uterine cancer in the United States.

Shelby Corman

e17009

Interdisciplinary surgery for advanced gynecologic malignancies: Outcome and complication rate.

Jelena Boeckhoff

e17002

KEYNOTE-826: a phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer.

Ronnie Shapira-Frommer

TPS5595

Mutational landscape of cervical cancer identified by prospective clinical sequencing in a nationwide cancer network.

Julian C. Schink

e17022

Overall survival trends for cervical cancer in the modern era: A U.S.A. population based analysis.

Andrew Jonathan Huang

e17024

Patient characteristics associated with treatment of cervical cancer in the United States.

Shelby Corman

e17020

PD-L1 expression, DNA mismatch repair genes, and HPV types in cervical squamous cell carcinoma.

Tahmineh Haidary

5533

Post-treatment clinical status of patients with cervical cancer.

Polina A. Kruze

e17007

Prognostic significance of the number of pelvic lymph-nodes resection in patients with cervical adenocarcinoma: An analysis from JGOG 1070S study.

Yuji Ikeda

5529

Prognostic value of tumor parameters measured by MRI in cervical cancer patients receiving CCRT.

Chang Sun

e17027

Recurrence and survival after robotic-assisted radical hysterectomy (RRH) for early-stage cervical cancer (CC): Experience may matter.

Christine K. Fitzsimmons

5535

Recurrence rates in cervical cancer patients treated with abdominal versus minimally invasive radical hysterectomy: A multi-institutional analysis of 700 cases.

Shitanshu Uppal

5504

Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for stage Ib2-IIb cervical cancer, EORTC 55994.

Gemma Kenter

5503

Revised FIGO staging shows dramatic survival differences in cervical cancer patients with positive lymph nodes in Louisiana.

Navya Nair

e17010

Safety and efficacy of nimotuzumab and concurrent intensity-modulated radiation therapy and chemotherapy for locally advanced cervical squamous cell cancer.

Ang Qu

5532

Significance of degree of destructive stromal invasion in early stage endocervical adenocarcinoma.

Jayanthi Sivasothy Lea

e17023

Single agent of apatinib in patients with recurrent or refractory cervical cancer: A real-world multicenter retrospective study.

Ning Li

e17011

Survival differences based on tumor size among stage 1B cervical cancer patients in Louisiana using revised FIGO staging system.

Navya Nair

e17017

Survival of patients with cervical cancer and diabetes: An exploratory study.

Maria Luisa Romero

e17008

The value of tumor paramaters and dosimetry on prognostic nomograms for cervical cancer.

Shun Lu

e17026

Treatment outcome for primary cervix large B-cell lymphoma: A clinical analysis of thirty-seven cases.

Xiaojian LIU

e17025

Trends in opioid use in patients undergoing primary surgery for cervical cancer.

Katherine Tucker

e17014

Trial in progress: Phase II study of stereotactic body radiation therapy and atezolizumab in the management of recurrent, persistent, or metastatic cervical cancer.

Kamran A. Ahmed

TPS5596

Uterine corpus invasion as a risk factor in patients with early-stage cervical carcinoma receiving radical surgery.

Yifan Li

e17012

Value of adjuvant chemotherapy using paclitaxel plus carboplatin after radical surgery with or without radiotherapy in stage IB-iia cervical adenocarcinoma with risk factors.

You Wu

e17016

Weighted gene co-expression network analysis combined with machine learning to identify prognostic biomarkers for cervical squamous cell carcinoma.

Yimin Li

e17000